{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:52:39Z","timestamp":1792432359290,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006254","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000}}],"reference-count":163,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006254.pub2","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T15:02:12Z","timestamp":1418137332000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients"],"prefix":"10.1002","volume":"2014","author":[{"given":"Angela E","family":"Ballinger","sequence":"first","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave Christchurch New Zealand 8041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave Christchurch New Zealand 8041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut","family":"Nistor","sequence":"additional","affiliation":[{"name":"\"Gr. T. Popa\" University of Medicine and Pharmacy; Nephrology Department; Bdul Carol I, No 50 Iasi Iasi Romania 700503"},{"name":"Ghent University Hospital; European Renal Best Practice Methods Support Team; Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden. Amedeo Avogadro University of Eastern Piedmont; Division of Nephrology and Transplantation, Department of Translational Medicine; Novara Italy 28100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,9]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"A34","DOI":"10.1053\/j.ajkd.2007.02.043","article-title":"Assessing the use of the calcimimetic cinacalcet with low dose vitamin D versus escalating doses of vitamin D alone in the treatment of secondary hyperparathyroidism (HPT) - The ACHIEVE Study [abstract no: 39]","volume":"49","author":"Charytan","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006254.pub2-BIB0002|cit2","first-page":"764A","article-title":"Efficacy of treatments targeting the calcium-sensing receptor (CaR) and vitamin D receptor (VDR) in controlling parathyroid hormone (PTH) in hemodialysis (HD) patients: cinacalcet HCI plus low-dose vitamin D vs flexible vitamin D alone [abstract no: SU-PO812]","volume":"18","author":"Charytan","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0003|cit3","first-page":"891A","article-title":"A comparison of cinacalcet HCI and low-dose vitamin D vs escalating doses of vitamin D alone - the ACHIEVE study [abstract no: PUB354]","volume":"17","author":"Fishbane","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006254.pub2-BIB0005|cit5","first-page":"vi363","article-title":"Cinacalcet with low dose vitamin D provides improved control of parathyroid hormone, calcium, and calcium-phosphorus product in hemodialysis patients with secondary hyperparathyroidism compared with vitamin D alone [abstract no: SaP383]","volume":"22","author":"Fishbane","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0006|cit6","first-page":"89A","article-title":"Treatment with cinacalcet HC1 and concurrent low-dose vitamin D improved management of secondary hyperparathyroidism (SHPT) compared with vitamin D alone [abstract no: SU-FC100]","volume":"18","author":"Fishbane","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1053\/j.ajkd.2010.07.012","article-title":"Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients","volume":"56","author":"Shireman","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006254.pub2-BIB0008|cit8","first-page":"739A","article-title":"Treatment with cinacalcet plus vitamin D results in lower FGF23 levels than vitamin D alone [abstract no: SA-PO2779]","volume":"19","author":"Wetmore","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/gfp762","article-title":"Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients","volume":"25","author":"Floege","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"A39","DOI":"10.1053\/j.ajkd.2007.02.065","article-title":"ADVANCE: the effect of cinacalcet + low-dose vitamin D on vascular calcification in hemodialysis patients - methods [abstract no: 60]","volume":"49","author":"Floege","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0013|cit13","first-page":"3B","article-title":"Efficacy of cinacalcet combined with low dose vitamin D in incident hemodialysis subjects with secondary hyperparathyroidism [abstract no: LB-PO3145]","volume":"22","author":"Urena","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","article-title":"Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"12","author":"Akiba","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0015|cit15","first-page":"503A","article-title":"Randomized, double blind, placebo-controlled, dose-finding parallel study for KRN1493 (cinacalcet HC1) in Japanese hemodialysis patients [abstract no: F-PO764]","volume":"16","author":"Akiba","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0016|cit16","first-page":"S13","article-title":"Clinical study of cinacalcet in Japan","volume":"12 Suppl 1","author":"Akizawa","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0017|cit17","first-page":"461A","article-title":"Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO743]","volume":"14","author":"Block","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"15","key":"10.1002\/14651858.CD006254.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0019|cit19","first-page":"464A","article-title":"Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]","volume":"14","author":"Coyne","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0020|cit20","unstructured":"Cunningham J Chertow G Goodman W Danese M Olson K Klassen P The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 219"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney international"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006254.pub2-BIB0022|cit22","first-page":"v89","article-title":"Cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) maintains achievement of NKF-K\/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]","volume":"20","author":"Frazao","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0023|cit23","first-page":"iv8","article-title":"Early use of cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]","volume":"21","author":"Frazao","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0024|cit24","unstructured":"Frazao JM Nicolini M Torresgrossa JV Kerr P Jaeger PH Sprague SM Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT) [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 219"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0025|cit25","first-page":"460A","article-title":"Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]","volume":"14","author":"Goodman","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0026|cit26","first-page":"863A","article-title":"Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0027|cit27","first-page":"280A","article-title":"Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0029|cit28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfh829","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism","volume":"20","author":"Lien","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006254.pub2-BIB0028|cit29","first-page":"A301","article-title":"Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism [abstract no: W-PO40084]","volume":"10","author":"Lien","year":"2005","journal-title":"Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0030|cit30","first-page":"462A","article-title":"Control of bio-intact parathyroid hormone (PTH) levels with the calcimimetic Cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract no: SA-PO747]","volume":"14","author":"Martin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0031|cit31","first-page":"A33","article-title":"Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]","volume":"43","author":"Mittman","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney international"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0033|cit33","first-page":"275A","article-title":"Long-term treatment of secondary hyperparathyroidism (HPT) with cinacalcet (SensiparTM) in patients receiving dialysis [abstract]","volume":"15","author":"Sterrett","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5414\/CNP68010","article-title":"Cinacalcet HCI (Sensipar\/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism","volume":"68","author":"Sterrett","year":"2007","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0035|cit35","unstructured":"de Francisco A Suranyi M Cunningham J Messa P Locatelli F Evenepoel P Greater achievement of NKF-K\/DOQI bone metabolism and disease targets with oral cinacalcet HCL in an EU\/Australian phase 3 study in haemodialysis subjects [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 319"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0036|cit36","first-page":"461A","article-title":"Oral cinacalcet HCI (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism (HPT): results of a European\/Australian phase 3 study. [abstract no: SA-PO742]","volume":"14","author":"Francisco","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0038|cit38","first-page":"460A","article-title":"Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis [abstract]","volume":"14","author":"Coburn","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0039|cit39","first-page":"A19","article-title":"Cinacalcet HCI reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD) [abstract no: 18]","volume":"43","author":"Chonchol","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0040|cit40","first-page":"533A","article-title":"A randomized, double-blind, placebo-controlled study of cinacalcet in CKD not on dialysis [abstract no: SA-PO867]","volume":"18","author":"Chonchol","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","volume":"53","author":"Chonchol","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","article-title":"Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients","volume":"15","author":"El-Shafey","year":"2011","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0043|cit43","first-page":"893A","article-title":"Evaluation of cinacalcet HCI therapy to lower cardiovascular events (EVOLVE) trial [abstract no: PUB359]","volume":"17","author":"Chertow","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD006254.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/ndt\/gfr777","article-title":"Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"27","author":"Chertow","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD006254.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview","volume":"2","author":"Chertow","year":"2007","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"26","key":"10.1002\/14651858.CD006254.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0047|cit47","first-page":"S13","article-title":"Clinical study of cinacalcet in Japan","volume":"12 Suppl 1","author":"Akizawa","year":"2008","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006254.pub2-BIB0048|cit48","first-page":"vi171","article-title":"Randomized, placebo-controlled trial of cinacalcet (KRN1493) in Japanese dialysis patients with more severe hyperparathyroidism and longer dialysis vintage [abstract no: FP453]","volume":"22","author":"Fukagawa","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0050|cit50","first-page":"889A","article-title":"A randomized, double blind, placebo-controlled, 14 week study to assess the efficacy and safety of cinacalcet HCI in Japanese hemodialysis patients [abstract no: PUB348]","volume":"17","author":"Yumita","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0051|cit51","first-page":"619A","article-title":"The calcimimetic, R-568, lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism [abstract]","volume":"10","author":"Goodman","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney International"},{"issue":"Sept","key":"10.1002\/14651858.CD006254.pub2-BIB0053|cit53","first-page":"576A","article-title":"Multiple doses of the calcimimetic AMG 073 reduce plasma parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT) [abstract]","volume":"11","author":"Goodman","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006254.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ndt\/gfr531","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006254.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney International"},{"issue":"Sept","key":"10.1002\/14651858.CD006254.pub2-BIB0059|cit59","first-page":"578A","article-title":"The calcimimetic AMG073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium x phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism (SHPT) [abstract]","volume":"11","author":"Lindberg","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0060|cit60","first-page":"464A","article-title":"Cinacalcet HCI controls secondary hyperparathyroidism (HPT) regardless of gender, race, age, and geography in patients with chronic kidney disease (CKD) receiving dialysis. [abstract no: SA-PO754]","volume":"14","author":"Coyne","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0061|cit61","unstructured":"Cunningham J Chertow G Goodman W Danese M Olson K Klassen P The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 219"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney international"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006254.pub2-BIB0063|cit63","first-page":"v89","article-title":"Cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) maintains achievement of NKF-K\/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis [abstract no: SP209]","volume":"20","author":"Frazao","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0064|cit64","first-page":"iv8","article-title":"Early use of cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) in dialysis patients enables greatest achievement of NKF-KDOQITM treatment targets for bone metabolism [abstract no: SO016]","volume":"21","author":"Frazao","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0065|cit65","unstructured":"Frazao JM Nicolini M Torresgrossa JV Kerr P Jaeger PH Sprague SM Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT) 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 219"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0066|cit66","first-page":"460A","article-title":"Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]","volume":"14","author":"Goodman","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0067|cit67","first-page":"863A","article-title":"Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0068|cit68","first-page":"280A","article-title":"Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0070|cit70","first-page":"463A","article-title":"Phase 3 experience with cinacalcet HCI in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT [abstract no: SA-PO752]","volume":"14","author":"Lindberg","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0071|cit71","first-page":"280A","article-title":"Cinacalcet HCI (SensiparTM) for the management of secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) [abstract no: F-PO985]","volume":"15","author":"Mittman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0072|cit72","first-page":"A33","article-title":"Phase 3 studies demonstrate effective control of PTH and Ca x P in patients treated with cinacalcet HCI [abstract no: 73]","volume":"43","author":"Mittman","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney international"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0074|cit74","unstructured":"Cunningham J Chertow G Goodman W Danese M Olson K Klassen P The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 219"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney international"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0076|cit76","first-page":"863A","article-title":"Cinacalcet HCI (SensiparTM) effectively manages secondary hyperparathyroidism (HPT) in new to dialysis patients [abstract no: PUB477]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD006254.pub2-BIB0077|cit77","first-page":"280A","article-title":"Cinacalcet HCI (SensiparTM) is an effective treatment for secondary hyperparathyroidism (HPT) in CKD patients on dialysis [abstract no: F-PO984]","volume":"15","author":"Goodman","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0079|cit79","unstructured":"Malluche HH Monier-Faugere MC Wang G Frazao JM Charytan C Coburn JW Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 218 9"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2369-13-76","article-title":"Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?","volume":"13","author":"Frazao","year":"2012","journal-title":"BMC Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0081|cit81","first-page":"A30","article-title":"The Optima Study: earlier intervention of cinacalcet HCL (Sensipar\u00a9\/Mimpara\u00a9) enables greater achievement of KDOQIT secondary hyperparathyroidism (SHPT) targets in dialysis patients [abstract no: 45]","volume":"47","author":"Frazao","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0082|cit82","first-page":"iv134","article-title":"Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) [abstract no: SP359]","volume":"21","author":"Gonzalez","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0083|cit83","first-page":"iv133","article-title":"The OPTIMA study: efficacy of a cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) treatment algorithm to treat dialysis patients with elevated PTH and calcium-phosphorus product (Ca x P) [abstract no: SP357]","volume":"21","author":"Locatelli","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0085|cit85","first-page":"501A","article-title":"Optimizing the use of cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) and vitamin D: interim results from the OPTIMA study [abstract no: F-PO758]","volume":"16","author":"Messa","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0086|cit86","first-page":"iv407","article-title":"The OPTIMA study: lower doses of cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) are required to achieve KDOQITM secondary hyperparathyroidism (HPT) targets in dialysis patients with less severe disease [abstract no: MP324]","volume":"21","author":"Messa","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0087|cit87","first-page":"iv136","article-title":"Use of cinacalcet HCL (Mimpara\u00a9\/Sensipar\u00a9) to control mineral metabolism in patients with end-stage renal disease (ESRD) on dialysis complicated by secondary hyperparathyroidism (SHPT): a cost-consequence analysis of cinacalcet HCL versus standard of care (SC) [abstract no: SP363]","volume":"21","author":"Perrault","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0090|cit88","unstructured":"Wilkie M A multi-centre, randomised, open-label study to compare the efficacy and safety of an oral calcimimetic agent (AMG 073) when two different vitamin D regimens are used in subjects with secondary hyperparathyroidism of end-stage renal disease (ESRD) http:\/\/www.nihr.ac.uk\/Profile\/Pages\/NRRResults.aspx?publication_id=N0059124801"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0088|cit89","first-page":"c41","article-title":"Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet","volume":"112","author":"Wilkie","year":"2009","journal-title":"Nephron"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0089|cit90","first-page":"iv134","article-title":"The OPTIMA study: optimising the dose of vitamin D (vit D) in the presence of cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) to obtain maximum clinical benefit [abstract no: SP358]","volume":"21","author":"Wilkie","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0092|cit92","first-page":"448","article-title":"A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients","volume":"22","author":"Al-Hilali","year":"2011","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD006254.pub2-BIB0093|cit93","first-page":"573A","article-title":"Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism [abstract]","volume":"11","author":"Coburn","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate","volume":"1","author":"Chertow","year":"2006","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0095|cit95","first-page":"280A","article-title":"The CONTROL STUDY: enhanced achievement of NKF-K\/DOQI bone metabolism and disease targets using cinacalcet HCL (Sensipar) [abstract]","volume":"15","author":"Reed","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0096|cit96","first-page":"150","article-title":"Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SPTH) [abstract no: M479]","volume":"18","author":"Cunningham","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006254.pub2-BIB0097|cit97","first-page":"v89","article-title":"Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD) [abstract no: SP210]","volume":"20","author":"Cunningham","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD006254.pub2-BIB0098|cit98","first-page":"v197","article-title":"Cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) effectively reduces intact parathyroid hormone (iPTH) and serum calcium (CA) regardless of serum calcium level in patients with secondary hyperparathyroidism (HPT) [abstract no: MO30]","volume":"20","author":"Francisco","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0099|cit99","first-page":"462A","article-title":"Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCI up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD) [abstract no: SA-PO746]","volume":"14","author":"Harris","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006254.pub2-BIB0100|cit100","first-page":"ii497","article-title":"Cinacalcet vs. paricalcitol in hemodialysis patients [abstract]","volume":"27","author":"Kaperonis","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0101|cit101","first-page":"463A","article-title":"Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCI [abstract no: SA-PO753]","volume":"14","author":"Moe","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD006254.pub2-BIB0102|cit102","first-page":"495A","article-title":"Cinacalcet lowers serum alkaline phosphatase (alkPhos) in maintenance hemodialysis (MHD) patients [abstract no: SA-PO698]","volume":"18","author":"Belozeroff","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0103|cit103","first-page":"501A","article-title":"Characterization of the effects of cinacalcet HC1 (Sensipar\u00a9\/Mimpara\u00a9) on serum calcium in dialysis patients with secondary hyperparathyroidism (HPT) [abstract no: F-PO756]","volume":"16","author":"Bushinsky","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD006254.pub2-BIB0104|cit104","first-page":"48A","article-title":"Achievement of proposed NKF-K\/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (HPT) [abstract no: SU-FC217]","volume":"14","author":"Moe","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0105|cit105","first-page":"501A","article-title":"Cinacalcet HC1 sustains long-term control of secondary hyperparathyroidism (HPT) [abstract no: F-PO755]","volume":"16","author":"Moe","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD006254.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0107|cit107","first-page":"461A","article-title":"Cinacalcet HCI absorption in study subjects is not affected by coadministration of medications commonly prescribed to chronic kidney disease (CKD) patients (pantoprazole, sevelamer HCI, and calcium carbonate). [abstract no: SA-PO744]","volume":"14","author":"Padhi","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.1996.31","article-title":"The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients","volume":"49","author":"Pahl","year":"1996","journal-title":"Kidney international"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0109|cit109","first-page":"463A","article-title":"Cinacalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity [abstract]","volume":"14","author":"Quarles","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CNP70126","article-title":"Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study","volume":"70","author":"Schaefer","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254.pub2-BIB0111|cit111","first-page":"iv288","article-title":"The SENSOR study: a study to evaluate the efficacy of administering cinacalcet (Mimpara\u00a9\/Sensipar\u00a9) with the first meal after dialysis [abstract no: MO003]","volume":"21","author":"Schaefer","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006254.pub2-BIB0112|cit112","first-page":"ii509","article-title":"Treatment of secondary hyperparathyroidism in maintenance hemodialysis patients: a randomised clinical trial comparing paricalcitol, calcitriol and cinacalcet [abstract]","volume":"27","author":"Sezer","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD006254.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism","volume":"23","author":"Block","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254.pub2-BIB0114|cit114","first-page":"863A","article-title":"Preliminary results from TARGET: treatment strategies to achieve recommended K\/DOQI goals in ESRD patients on Cinacalcet [abstract]","volume":"15","author":"Chertow","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1542-4758.2011.00642.x","article-title":"Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols","volume":"16","author":"Chertow","year":"2012","journal-title":"Hemodialysis International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0116|cit116","first-page":"460A","article-title":"Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney diseases (CKD) not receiving dialysis [abstract]","volume":"14","author":"Coburn","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD006254.pub2-BIB0117|cit117","first-page":"764A","article-title":"Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073 [abstract]","volume":"12","author":"Drueke","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0118|cit118","unstructured":"Fournier A Pontoiero G Walker R Martin-Malo A Wilkie M Coyne DW Cinacalcet HCL reduces parathyroid hormone (PTH) and calcium-phosphate product (Ca x P) regardless of concurrent changes in vitamin D administration [abstract] 41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal) 2004 319"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0119|cit119","unstructured":"University of Pennsylvania Renal Electrolyte Hypertension Division. 2004 A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of a calcimimetic agent (AMG 073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency http:\/\/www.uphs.upenn.edu\/renal\/research\/clinical_research_chronic_kidney.html"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200363060-00005","article-title":"Hyperphosphataemia in renal failure: causes, consequences and current management","volume":"63","author":"Albaaj","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0272-6386(96)90396-0","article-title":"Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia","volume":"28","author":"Avram","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006254.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006254.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006254.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1600-6143.2004.00583.x","article-title":"Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation","volume":"4","author":"Borrows","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006254.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1681\/ASN.V86965","article-title":"Lower probability of patient survival with continuous peritoneal dialysis in the united states compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group","volume":"8","author":"Churchill","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8-9","key":"10.1002\/14651858.CD006254.pub2-BIB0127|cit127","first-page":"327","article-title":"Surgical treatment of secondary hyperparathyroidism in chronic kidney failure. Results of total parathyroidectomy with parathyroid autotransplantation","volume":"130","author":"Courant","year":"1993","journal-title":"Journal de Chirurgie"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney international"},{"issue":"7124","key":"10.1002\/14651858.CD006254.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0130|cit130","unstructured":"US Food Drug Administration Sensipar (cinacalcet HCl) tablets http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/ucm194427.htm"},{"issue":"10","key":"10.1002\/14651858.CD006254.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patient","volume":"12","author":"Ganesh","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7650","key":"10.1002\/14651858.CD006254.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD006254.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0134|cit134","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD006254.pub2-BIB0135|cit135","first-page":"622","article-title":"Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease","volume":"26","author":"Hutchison","year":"1995","journal-title":"Kidney international"},{"issue":"7384","key":"10.1002\/14651858.CD006254.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.326.7384.334","article-title":"Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity","volume":"326","author":"Juni","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0137|cit137","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1523-1755.2004.00368.x","article-title":"Parathyroidectomy rates among United States dialysis patients: 1990-1999","volume":"65","author":"Kestenbaum","year":"2004","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD006254.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0140|cit140","unstructured":"KHA-CARI guidelines http:\/\/www.cari.org.au\/"},{"issue":"7400","key":"10.1002\/14651858.CD006254.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ndt\/gfh1002","article-title":"The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?","volume":"19 Suppl 1","author":"Malluche","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","article-title":"Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population","volume":"85","author":"Marco","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/01.ASN.0000130566.69170.5E","article-title":"Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease","volume":"15","author":"McMahon","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD006254.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1096\/fj.06-6304fje","article-title":"The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis","volume":"20","author":"Mentaverri","year":"2006","journal-title":"FASEB Journal"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbrc.2007.07.177","article-title":"Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells","volume":"362","author":"Mizobuchi","year":"2007","journal-title":"Biochemical & Biophysical Research Communications"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0148|cit148","unstructured":"NICE: National Institute for Health and Care Excellence TA117 Hyperparathyroidism - cinacalcet guidance (24 January 2007) http:\/\/guidance.nice.org.uk\/TA117\/Guidance\/"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD006254.pub2-BIB0149|cit149","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD006254.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.282.8.786","article-title":"Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease","volume":"282","author":"Psaty","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0272-6386(95)90599-5","article-title":"Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis","volume":"26","author":"Qi","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006254.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias: the case for an international registry of clinical trials","volume":"4","author":"Simes","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006254.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnephrol.2003.08.013","article-title":"Osteoporosis and chronic kidney disease","volume":"24","author":"Stehman-Breen","year":"2004","journal-title":"Seminars in Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006254.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006254.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1523-1755.63.s85.22.x","article-title":"Calcimimetic agents: review and perspectives","volume":"85","author":"Urena","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD006254.pub2-BIB0157|cit157","first-page":"e1","article-title":"United States Renal Data System 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States","volume":"61","author":"Collins","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006254.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","article-title":"Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity","volume":"26","author":"Wang","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006254.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","article-title":"Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease","volume":"48","author":"Weiner","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006254.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1651-2227.2000.tb00361.x","article-title":"Bone biopsy results and serum bone turnover parameters in uremic children","volume":"89","author":"Ziolkowska","year":"2000","journal-title":"Acta Paediatrica"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006254.pub2-BIB0162|cit162","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006254","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006254.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"American Journal of Kidney Diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006254.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:05:25Z","timestamp":1698645925000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006254.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,9]]},"references-count":163,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006254.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725270008.793502999","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,9]]}}}